Evidence map›Paper›PMID 30662004›Full record

Trial reportThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2019

Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial.

İlkay Yılmaz, M Enver Dolar, Haydar Özpınar

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 15 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 15 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Interventions for the management of abdominal pain in ulcerative colitis.The Cochrane database of systematic reviews · 2021
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Probiotics for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2020
    Pooled it
  14. Probiotics for maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2020
    Pooled it
  15. Probiotics for induction of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2020
    Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

İlkay YılmazDepartment of Food Engineering, İstanbul Aydın University, İstanbul, Turkey.
M Enver DolarDepartment of Internal Medicine and Gastroenterology, Uludağ University School of Medicine, Bursa, Turkey.
Haydar ÖzpınarGraduate School of Health Sciences, Istanbul Gedik University, İstanbul, Turkey.
Bursa Uludağ Üni̇versi̇tesi̇ · TRGedik University · TRIstanbul Aydın University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsKefir is a kind of fermented probiotic dairy product. The objective of the present study was to investigate the effects of kefir consumption on the fecal microflora and symptoms of patients with inflammatory bowel disease (IBD). MATERIALS AND

methodsKefir was serially diluted and inoculated into de Man, Rogosa, and Sharpe agar and incubated at 37°C for 48 to 72 h under anaerobic conditions. This was a single-center, prospective, open-label randomized controlled trial. Forty-five patients with IBD were classified into two groups: 25 for treatment and 20 for control. A 400 mL/day kefir was administered to the patients for 4 weeks day and night. Their stool Lactobacillus, Lactobacillus kefiri, content was quantitated by real-time quantitative polymerase chain reaction before and after consumption. Abdominal pain, bloating, stool frequency, stool consistency, and feeling good scores were recorded in diaries daily by the patients.

resultsA 5×107 CFU/mL count of lactic acid bacteria colony forming units was found in a kefir sample as the total average count. Lactobacillus bacterial load of feces of all subjects in the treatment group was between 104 and 109 CFU/g, and the first and last measurements were statistically significant (p=0.001 in ulcerative colitis and p=0.005 in Crohn's disease (CD)). The L. kefiri bacterial load in the stool of 17 subjects was measured as between 104 and 106 CFU/g. For patients with CD, there was a significant decrease in erythrocyte sedimentation rate and C-reactive protein, whereas hemoglobin increased, and for the last 2 weeks, bloating scores were significantly reduced (p=0.012), and feeling good scores increased (p=0.032).

conclusionAccording to our data, kefir consumption may modulate gut microbiota, and regular consumption of kefir may improve the patient's quality of life in the short term.

Indexed as

Gastrointestinal MicrobiomeAdultBacterial LoadBlood SedimentationColitis, UlcerativeC-Reactive ProteinCrohn DiseaseFecesFemaleHumansInflammatory Bowel DiseasesKefirLactobacillusMaleMiddle AgedProbioticsC-Reactive Protein

Identifiers

PMID30662004
PMCPMC6428516
OpenAlexW2898293044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.